Expensify Inc vs TransMedics Group Inc — how do they compare? Expensify Inc trades at $1.82 (market cap $170.21M), while TransMedics Group Inc trades at $77.86 (market cap $2.61B). The key difference: TransMedics Group Inc is far larger — about 15.3× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| EXFY | TMDX | |
|---|---|---|
Market Cap | $170.21M | $2.61B |
Sector | Technology | Technology |
52-Week High | $2.33 | $150.42 |
52-Week Low | $0.75 | $61.99 |
Enterprise Value | $109.24M | $3.01B |
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $1.755, down 3.04% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.04, beating expectations, but maintains negative profitability metrics with a -14.68% net income margin. Recent developments include AI-powered expense management expansions and a $25 million stock repurchase program, indicating strategic initiatives to drive growth.
The outlook remains cautious due to persistent unprofitability despite revenue stabilization around $140 million. Investment opportunities lie in operational efficiency gains and new product integrations, but risks include competitive pressure and the challenge of achieving sustainable profitability. Analyst sentiment is divided with equal buy/hold ratings, reflecting uncertainty about the company's turnaround potential.
No Aura AI signal available yet.
Trailing returns across standard periods
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →